Ocular Therapeutix (OCUL) announced that its SOL-R registrational trial of AXPAXLI in wet age-related macular degeneration has achieved its randomization target of 555 subjects. Ocular will continue to allow randomization of previously enrolled subjects currently in the loading phase of the trial to maintain its commitment to both patients and investigators, with topline data remaining on track for the first half of 2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix reports Q3 EPS (38c), consensus (35c)
- OCUL Earnings this Week: How Will it Perform?
- Ocular Therapeutix price target raised to $20 from $14 at TD Cowen
- Optimistic Buy Rating for Ocular Therapeutix Driven by Axpaxli’s Market Potential in wAMD and NPDR
- Insider Moves: Ross, Carisma, Agree, Aehr, Ocular